Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Sponsor
University of Tartu
Study ID
NCT02089256
Phase
PHASE4
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • Liraglutide — DRUG
    Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated. GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).

Study Details

The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.

Key Dates

Start date
Jun 30, 2014
Status verified
Mar 2015
Primary completion
Mar 31, 2015
Completion
Mar 31, 2015

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Liraglutide 0.6 mg/day subcutaneously.

Primary Outcome Measure

Change in the glucose-sensitivity of the beta cells [ Time Frame: baseline, first dose, after 3-weeks on treatment ]

Related Studies